AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+1.51%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.33x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.53x
- Price / sales
- 0.86x
- Price / cash flow
- 4.54x
Enterprise value
- Enterprise value
- $86.9M
- EV / sales
- 0.40x
- EV / EBITDA
- -4.74x
- EV / EBIT
- -5.74x
- Market cap
- $188.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026